 Orphazyme AS NASDAQ: ORPH shares, which have been extremely volatile of late, could come under pressure Friday following a regulatory setback. What Happened: Denmark-based Orphazyme said its new drug application, seeking approval for arimoclomol as a treatment option for Niemann-Pick disease type C NPC, was turned down with a complete response letter. 